UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2019-09, Vol.381 (13), p.1201-1214

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

The New England journal of medicine, 2015-07, Vol.373 (2), p.136-144

2015

Link zum Volltext

Verfügbarkeit prüfen

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Journal of the American Academy of Dermatology, 2015-10, Vol.73 (4), p.594-603

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia

The New England journal of medicine, 2007-01, Vol.356 (2), p.148-156

2007

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial of a Low-Carbohydrate Diet for Obesity

The New England journal of medicine, 2003-05, Vol.348 (21), p.2082-2090

2003

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1675-1684

2008

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Journal of the American Academy of Dermatology, 2012-05, Vol.66 (5), p.742-751

2012

Link zum Volltext

Verfügbarkeit prüfen

Novel Image-Guided Flexible-Probe Transbronchial Microwave Ablation for Stage 1 Lung Cancer

Respiration, 2023-03, Vol.102 (3), p.182-193

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

Journal of the American Academy of Dermatology, 2012-05, Vol.66 (5), p.731-741

2012

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans

Journal of the American College of Cardiology, 2008-04, Vol.51 (17), p.1653-1662

2008

Link zum Volltext

Verfügbarkeit prüfen

A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity

The American journal of clinical nutrition, 2012-08, Vol.96 (2), p.249-254

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

Journal of dermatological science, 2011-09, Vol.63 (3), p.154-163

2011

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.457-465

2010

Link zum Volltext

Verfügbarkeit prüfen

Flaxseed and Cardiovascular Risk

Nutrition reviews, 2004-01, Vol.62 (1), p.18-27

2004

Link zum Volltext

Verfügbarkeit prüfen

CXCL16 Is a Marker of Inflammation, Atherosclerosis, and Acute Coronary Syndromes in Humans

Journal of the American College of Cardiology, 2007-01, Vol.49 (4), p.442-449

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)

Journal of drugs in dermatology, 2013-02, Vol.12 (2), p.166

2013

Link zum Volltext

Verfügbarkeit prüfen

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2012-07, Vol.67 (1), p.76-85

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

Journal of the American Academy of Dermatology, 2010-10, Vol.63 (4), p.571-579

2010

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

Annals of the New York Academy of Sciences, 2009-12, Vol.1182 (1), p.97-110

2009

Link zum Volltext

Verfügbarkeit prüfen

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

Arteriosclerosis, thrombosis, and vascular biology, 2006-01, Vol.26 (1), p.182

2006

Link zum Volltext

Verfügbarkeit prüfen

Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint

Journal of pharmacokinetics and pharmacodynamics, 2014-08, Vol.41 (4), p.335-349

2014

Link zum Volltext

Verfügbarkeit prüfen

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease

Journal of pharmacokinetics and pharmacodynamics, 2017-10, Vol.44 (5), p.425-436

2017

Link zum Volltext

Verfügbarkeit prüfen

The triglyceride–high-density lipoprotein axis: An important target of therapy?

The American heart journal, 2004-08, Vol.148 (2), p.211-221

2004

Link zum Volltext

Verfügbarkeit prüfen

Antidiabetic Action of Bezafibrate in a Large Observational Database

Diabetes care, 2009-04, Vol.32 (4), p.547-551

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(110)
Buchkapitel
(1)

Sprache

Englisch
(111)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Humans
(57)
Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Male
(35)
Female
(33)
Middle Aged
(27)
Adult
(26)
Biological And Medical Sciences
(24)
Treatment Outcome
(22)
Medical Sciences
(20)
Double-Blind Method
(19)
Psoriasis - Drug Therapy
(19)
Ustekinumab
(19)
Dermatology
(17)
Dose-Response Relationship, Drug
(16)
Psoriasis
(16)
Severity Of Illness Index
(14)
Antibodies, Monoclonal - Therapeutic Use
(13)
Antibodies, Monoclonal, Humanized
(13)
Aged
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia

A Randomized Trial of a Low-Carbohydrate Diet for Obesity

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Novel Image-Guided Flexible-Probe Transbronchial Microwave Ablation for Stage 1 Lung Cancer

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans

A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Flaxseed and Cardiovascular Risk

CXCL16 Is a Marker of Inflammation, Atherosclerosis, and Acute Coronary Syndromes in Humans

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease

The triglyceride–high-density lipoprotein axis: An important target of therapy?

Antidiabetic Action of Bezafibrate in a Large Observational Database

Suchergebnisse filtern